Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 9/2007

01-09-2007 | Case Report

Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges

Authors: E. Montané, M. Sallés, A. Barriocanal, E. Riera, J. Costa, X. Tena

Published in: Clinical Rheumatology | Issue 9/2007

Login to get access

Abstract

A 50-year-old man with ankylosing spondylitis who developed neutropenia after treatment of etanercept, with two positive rechallenges, and after the first infliximab infusion, is described. Although leukopenia and neutropenia related to etanercept and infliximab have been described as rare adverse events from clinical trials data, their mechanism of action are unknown. This patient developed recurrent mild neutropenia after exposition of two different antitumor necrosis factors; therefore, it seems to be an adverse reaction related to the therapeutic group. Doctors should be aware of this potentially severe adverse effect in patients treated with antitumor necrosis factor.
Literature
1.
Khanna D, McMahon M, Furst DE (2004) Safety of tumor necrosis factor-α antagonists. Drug Saf 27:307–324PubMedCrossRef
2.
3.
Hyrich KL, Silman AJ, Watson KD, Symmons DPM (2004) Anti-tumor necrosis factor α therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 63:1538–1543PubMedCrossRef
4.
Fleischmann R, Iqbal I, Nandeshwar P, Quiceno A (2002) Safety and efficacy of disease-modifying anti-rheumatic agents. Drug Saf 25:173–197PubMedCrossRef
5.
Malgarini RB, Pimpinella G (2004) Etanercept and methotrexate in rheumatoid arthritis. Lancet 363:1733PubMedCrossRef
6.
Feltelius N, Fored CM, Blomqvist P, Bertilsson L, Geborek P, Jacobsson LT et al (2005) Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 64:246–252PubMedCrossRef
7.
Berliner N, Horwitz M, Loughran TP (2004) Congenital and acquired neutropenia. Hematology (Am Soc Hematol Educ Program) 2004:63–79
8.
Strom BL, Carson JL, Schinnar R, Snyder ES, Shaw M, Lundin FE Jr (1993) Nonsteroidal anti-inflammatory drugs and neutropenia. Arch Intern Med 153:2119–2124PubMedCrossRef
9.
Vidal F, Fontova R, Richart C (2003) Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med 139:W–W63PubMed
10.
Ghavami A, Genevay S, Fulpius T, Gabay C (2005) Etanercept in treatment of Felty’s syndrome. Ann Rheum Dis 64:1090–1091PubMedCrossRef
11.
Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R et al (2004) Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 50:1412–1419PubMedCrossRef
12.
Phelan C, Wooltorton E (2004) Infliximab and serious hematologic events. Can Med Assoc J 171:1045CrossRef
13.
Menon Y, Cucurull E, Espinoza LR (2003) Pancytopenia in a patient with scleroderma treated with infliximab. Rheumatology 42:1273–1274PubMedCrossRef
14.
Favalli EG, Varenna M, Sinigaglia L (2005) Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy. Clin Exp Rheumatol 23:247–250PubMed
Metadata
Title
Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges
Authors
E. Montané
M. Sallés
A. Barriocanal
E. Riera
J. Costa
X. Tena
Publication date
01-09-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 9/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0415-y

Other articles of this Issue 9/2007

Clinical Rheumatology 9/2007 Go to the issue

Case Report

A case of polymyositis complicated with myasthenic crisis

Original Article

A national survey to assess investigation and management protocols followed in dealing with steroid-induced osteoporosis

Review Article

Translating evidence into practice for people with osteoarthritis of the hip and knee

Case Report

Cutaneous leukocytoclastic vasculitis associated with mycobacterial and salmonella infection

Case Report

Influence of corticosteroid treatment on MRI findings in giant cell arteritis

Case Report

Mixed connective tissue disease: a case with scleroderma renal crisis following abortion
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits